Review Article Endocrinology/Diabetes/Metabolism Plastic Surgery
Continuous glucose monitoring and health-related quality of life in patients with heart failure: A cross-sectional survey

Continuous glucose monitoring and health-related quality of life in patients with heart failure: A cross-sectional survey

Authors

Hugo Osei

Hugo Osei

Toronto General Hospital, Falkland Islands

Corresponding
Hugo Costa

Hugo Costa

Karolinska University Hospital, Paraguay

Ines Moreau

Ines Moreau

St Thomas' Hospital, Sudan

Lina Silva

Lina Silva

Mayo Clinic, Latvia

Layla Rossi

Layla Rossi

King Fahad Medical City, Uruguay

Published

July 25, 2024

Paper ID

PAP-000066

Status

Published

DOI

10.65712/tmj.test000324

Continuous glucose monitoring and health-related quality of life in patients with heart failure: A cross-sectional survey

Advance Services

Create Content

Video • Presentation • Poster

From $97.00 per format

Abstract

Background: Practice around continuous glucose monitoring varies widely between centres. Methods: Analyses were adjusted for age, sex and baseline severity. Results: 4264 participants were included (median age 48 years). 1713 participants were included (median age 71 years). Conclusion: Strengths include the sample size and blinded outcome assessment.

Introduction

The cost of health-related quality of life to health systems is substantial. health-related quality of life remains a leading cause of avoidable harm among patients with heart failure. Earlier studies of continuous glucose monitoring were small or single-centre.

Earlier studies of continuous glucose monitoring were small or single-centre. Guidelines make only a weak recommendation on continuous glucose monitoring. health-related quality of life remains a leading cause of avoidable harm among patients with heart failure.

Materials and Methods

Eligible participants were patients with heart failure. The primary outcome was health-related quality of life, assessed blind to allocation. We conducted a cross-sectional survey across 9 centres between 2016 and 2024.

Eligible participants were patients with heart failure. We conducted a cross-sectional survey across 10 centres between 2014 and 2023.

Analyses were adjusted for age, sex and baseline severity. Eligible participants were patients with heart failure.

We conducted a cross-sectional survey across 12 centres between 2020 and 2024. Missing data were handled with multiple imputation.

Results

health-related quality of life occurred in 20% of the intervention group versus 12% of controls. The adjusted odds ratio was 0.71 (95% CI 0.43 to 0.95). 1319 participants were included (median age 47 years). The adjusted odds ratio was 0.83 (95% CI 0.32 to 0.97).

Serious adverse events were rare and similar between groups. 4050 participants were included (median age 43 years).

GroupnEventsRate %OR
Centre B6501333.60.86
Centre B54910617.20.64
Male5331433.00.83
Centre A343923.80.95
Centre B26820.60.46
Age ≥ 65810112.30.43
TABLE 1: Secondary outcomes
Values are n (%) unless stated otherwise.
Figure 1
FIGURE 1: Distribution of health-related quality of life
Shown for patients with heart failure; error bars are 95% confidence intervals.

The adjusted odds ratio was 0.42 (95% CI 0.23 to 0.78). health-related quality of life occurred in 11% of the intervention group versus 25% of controls.

4021 participants were included (median age 45 years). Serious adverse events were rare and similar between groups. health-related quality of life occurred in 10% of the intervention group versus 24% of controls.

Discussion

Residual confounding cannot be excluded. Implementation will depend on staffing, cost and local protocols.

These findings suggest that continuous glucose monitoring is associated with better health-related quality of life in patients with heart failure. Strengths include the sample size and blinded outcome assessment.

Residual confounding cannot be excluded. Implementation will depend on staffing, cost and local protocols.

Conclusions

Continuous glucose monitoring merits wider use for patients with heart failure to improve health-related quality of life.

References

1. Ahmed X, Rahman I, et al. Vitamin D supplementation and medication adherence. BMC Med. 2025;79(5):272-1782.

2. Nasser V, Mueller V, et al. SGLT2 inhibitors and patient satisfaction. JAMA. 2016;237(2):576-1088.

3. Volkov W, Mensah Q, et al. Low-dose aspirin and time to diagnosis. Diabetes Care. 2018;158(5):626-1313.

4. Farouk V, Nasser Y, et al. Point-of-care ultrasound and glycaemic control. Diabetes Care. 2019;383(9):116-1068.

5. Novak S, Ahmed Y, et al. Early enteral nutrition and ventilator-free days. Pediatrics. 2023;281(6):47-1354.

6. Lindqvist T, Nakamura T, et al. Home-based cardiac rehabilitation and acute kidney injury. Crit Care Med. 2013;100(3):746-1474.

Appendices

Supplementary tables are available on request.